Previous 10 | Next 10 |
home / stock / ocul / ocul articles
BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutical company committed to e...
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six mont...
BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")), a biopharmaceutical company...
Ocular Therapeutix, Inc. (NASDAQ: OCUL) reported worse-than-expected fourth-quarter financial results on Monday. Ocular Therapeutix posted GAAP lo...
Shares of Oracle Corporation (NYSE: ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earnings for its fisc...
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. Shares of ACADIA Pharmaceuticals Inc ...
Shares of Fangdd Network Group Ltd. (NASDAQ: DUO) rose sharply in today’s pre-market trading after the company announced its 2024 strategic ...
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence...
Shares of Etsy, Inc. (NASDAQ: ETSY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial result...
News, Short Squeeze, Breakout and More Instantly...
Ocular Therapeutix Inc. Company Name:
OCUL Stock Symbol:
NASDAQ Market:
Ocular Therapeutix Inc. Website:
BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye c...
SOL-R evaluates repeat AXPAXLI™ dosing for wet age-related macular degeneration (wet AMD) Global non-inferiority study comparing AXPAXLI, dosed every six months, to 2 mg aflibercept every eight weeks BEDFORD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc....
BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative...